William HK Schilling
A5021949209- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Antibiotic Use and Resistance
- Respiratory viral infections research
- Long-Term Effects of COVID-19
- Bacterial Identification and Susceptibility Testing
- Sepsis Diagnosis and Treatment
- Parasitic Diseases Research and Treatment
- Streptococcal Infections and Treatments
- Antibiotic Resistance in Bacteria
- Mosquito-borne diseases and control
- Pharmaceutical Practices and Patient Outcomes
- Tryptophan and brain disorders
- SARS-CoV-2 detection and testing
- COVID-19 and Mental Health
- Urinary Tract Infections Management
- Infective Endocarditis Diagnosis and Management
- Malaria Research and Control
- COVID-19 and healthcare impacts
- PARP inhibition in cancer therapy
- Parasites and Host Interactions
- Global Maternal and Child Health
- Skin Diseases and Diabetes
- Pharmacological Receptor Mechanisms and Effects
- Clostridium difficile and Clostridium perfringens research
University of Oxford
2020-2025
Mahidol Oxford Tropical Medicine Research Unit
2020-2025
Mahidol University
2020-2025
Angkor Hospital for Children
2023-2024
John Radcliffe Hospital
2021
Wellcome Centre for Ethics and Humanities
2021
University of KwaZulu-Natal
2021
National University of Singapore
2021
London School of Hygiene & Tropical Medicine
2021
Royal Sussex County Hospital
2019-2020
Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different treatments using rate viral clearance as measure effect.
Abstract Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir been recommended for the treatment of some countries. Methods a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with were randomised one ten arms including...
Effective antiviral drugs prevent hospitalisation and death from COVID-19. Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 clearance estimated serial viral genome densities quantitated nasopharyngeal or oropharyngeal swab eluates. We conducted an individual patient data meta-analysis unblinded arms the PLATCOV platform trial to characterise changes kinetics infer optimal design interpretation pharmacometric evaluations.
Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus disease 2019 (COVID-19) has resulted varying treatment guidelines.In a multicenter open-label, controlled, adaptive, pharmacometric platform trial, low-risk adult patients with early symptomatic COVID-19 were randomized to 1 8 arms including intravenous (200 mg followed by 100 daily for 5 days) or no study drug. The primary outcome was rate severe acute respiratory syndrome 2 (SARS-CoV-2) clearance (estimated...
Pharmacometric assessment of antiviral efficacy in acute influenza informs treatment decisions and pandemic preparedness. We assessed natural viral clearance untreated to guide clinical trial design. Standardized duplicate oropharyngeal swabs were collected daily over 14 days from 80 low-risk Thai adults, with densities measured using qPCR. evaluated three models describe clearance: exponential, bi-exponential, growth-and-decay. The growth-and-decay model provided the best fit, but...
In rural areas of South and Southeast Asia malaria is declining but febrile illnesses still account for substantial morbidity mortality. Village health workers (VHWs) are often the first point contact with formal system, patients they can provide early diagnosis treatment malaria. However, majority patients, VHWs lack training, support resources to further care. Consequently, treatable bacterial missed, antibiotics overused poorly targeted, patient attendance wanes along This Open Letter...
Background: There is no generally accepted methodology for in vivo assessment of antiviral activity SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment COVID-19, but whether it clinically significant uncertain. Methods: In multicentre open label, randomized, controlled adaptive platform trial, adult patients with early symptomatic COVID-19 were randomized to one six arms including high-dose oral ivermectin (600 µg/kg daily 7 days), the monoclonal antibodies...
Abstract Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro , observational clinical trial evidence suggesting they prevented progression to severe disease. However, these SSRIs have not been recommended guidelines vivo has characterised. Methods PLATCOV is an open-label, multicentre, phase 2, randomised, controlled, adaptive pharmacometric platform running...
Background Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis suggest clinical benefit, guidelines recommend use. Methods findings Healthy adult participants from the healthcare setting, later community,...
Background Reporting cumulative antimicrobial susceptibility testing data on a regular basis is crucial to inform resistance (AMR) action plans at local, national, and global levels. However, analyzing generating report are time consuming often require trained personnel. Objective This study aimed develop test an application that can support local hospital analyze routinely collected electronic independently generate AMR surveillance reports rapidly. Methods An offline standardized from...
<ns3:p>In rural areas of South and Southeast Asia malaria is declining but febrile illnesses still account for substantial morbidity mortality. Village health workers (VHWs) are often the first point contact with formal system, patients they can provide early diagnosis treatment malaria. However, majority patients, VHWs lack training, support resources to further care. Consequently, treatable bacterial missed, antibiotics overused poorly targeted, patient attendance wanes along...
Background Uncertainty over the therapeutic benefit provided by parenteral remdesivir in COVID-19 has resulted varying treatment guidelines. Early pandemic monoclonal antibody cocktail, casirivimab/imdevimab, proved highly effective clinical trials but because of weak or absent vitro activity against SARS-CoV-2 Omicron BA.1 subvariant, it is no longer recommended. Methods In a multicenter open label, randomized, controlled adaptive platform trial, low-risk adult patients with early...
Introduction: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years malaria rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, ready availability made them prime repurposing therapeutic candidates at the beginning of COVID-19 pandemic.
Abstract Background Effective antiviral drugs prevent hospitalisation and death in COVID-19. Antiviral efficacy can be assessed efficiently in-vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral genome densities quantitated nasopharyngeal or oropharyngeal swab eluates. We carried out an individual patient data meta-analysis unblinded arms the PLATCOV platform trial to characterise changes kinetics infer optimal design interpretation pharmacometric evaluations. is...
<ns3:p>There is no proven preventative therapy or vaccine against COVID-19. Theinfection has spread rapidly and there already been a substantial adverse impact on the global economy. Healthcare workers have affected disproportionately in continuing pandemic. Significant infection rates this critical group resulted breakdown of health services some countries. Chloroquine, closely related hydroxychloroquine, are safe well tolerated medications which can be given for years without effects....
The World Health Organization living guideline on drugs to prevent COVID-19 has recently advised that ongoing trials evaluating hydroxychloroquine in chemoprophylaxis should stop. WHO cites "high certainty" evidence from randomised controlled (RCTs) prophylaxis does not reduce mortality and hospital admission, "moderate of poor tolerability because a significantly increased rate adverse events leading drug discontinuation. Yet there is no such evidence. In the three pre-exposure RCTs...
Abstract Background: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir been recommended for the treatment of COVID-19 some countries. Methods: In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic were randomised one ten arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily complete 7 days...